News
Quotient Sciences Conducts Integrated Translational Pharmaceutics Program in U.S. With Druggability Technologies
Quotient Sciences, a leading drug development services organization, and Druggability Technologies (DRGT), a specialty pharmaceutical company, announced a collaboration to utilize Quotientโs integrated Translational...
Articles
Injecting New Blood into the Life Sciences Innovation Process
Innovation and collaboration are the lifeblood of the life sciences. Without them, both research and business come to a standstill.
Knowing this, how do pharmaceutical...
Press Releases
Axol Bioscience Launches Human iPSC-derived Microglia
Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and...
Press Releases
Genoscience Pharma named EuropaBioโs Most Innovative European Biotech SME for 2018
Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing anticancer drugs, is delighted to announce that it received the Most Innovative European...
News
Industry Leaders Join Forces to Discuss Optimizing eConsent for Patient Centricity
Informative webinar hosted by CRF Health, a CRF Bracket company, will address how eConsent can be implemented effectively to support patient centricity and improve...
Press Releases
New Digital Marketplace for Life Science Products โ Built with Scientists in Mind
Labviva, an AI-powered digital marketplace for life science reagents, instrumentation and services announces its launch to create scientifically informed purchasing decisions. ...
Research Insight
Eisai and UCLommence preparations for phase i clinical studies in Alzheimer’s Disease for Novel Anti-Tau Antibody
Eisai Co., Ltdย and University College Londonย ย announcedย that they have commenced preparations for Phase I clinical studies on E2814 The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read













